Tradestie Institutional Equity Comparison Engine

NUVB vs STOK โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

STOK Overall Edge

STOK Captures Institutional Edge (2โ€“1 Pillars ยท 4โ€“4 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Stoke Therapeutics, Inc. Common Stock (STOK) driven by superior Momentum & Technical, Options & Structure while NUVB counters with relative strength in Growth & Margin. Fundamentally, NUVB trades at N/M Forward P/E with -61.2% operating margin (+242.6% YoY revenue) versus STOK at N/M Forward P/E and -913.2% operating margin (+5.9% YoY). In options structure, NUVB sits in BREAKDOWN (26th %ile IV; Dealer Gamma Walls on Pro) against STOK sits in SURGE (8th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
NUVB N/M vs STOK N/M Fwd P/E
Growth & Margin Winner NUVB
Op Margin -61.2% vs -913.2% ยท YoY +242.6% vs +5.9%
Momentum & Technical Winner STOK
1Y -46.9% vs -5.9% ยท 52W Pos 2% vs 26%
Options & Structure Winner STOK
BREAKDOWN (26th %ile IV) vs SURGE (8th %ile IV)
NUVB NYSE
Nuvation Bio Inc.
Pharmaceutical Preparations
$3.80
-0.26% 1D
Market Cap $1.3B
1M Return -19.15%
1Y Return -46.85%
Forward P/E N/M
Unified AI Score
61.0 / 100 BUY
Tech 53.0 Fund 61.0 Flow 67.0 Mom 64.0
STOK NASDAQ
Stoke Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$26.81
-0.45% 1D
Market Cap $1.8B
1M Return +4.32%
1Y Return -5.86%
Forward P/E N/M
Unified AI Score
55.9 / 100 HOLD
Tech 43.0 Fund 56.0 Flow 64.0 Mom 60.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: NUVB -46.85% STOK -5.86% Spread: +40.99 pp (STOK Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period NUVB Revenue STOK Revenue NUVB Op. Margin STOK Op. Margin Margin Edge
FY2022 N/A $10M N/A -841.2% STOK
FY2023 N/A $10M N/A -1307.2% STOK
FY2024 $10M $40M -7527.3% -277.3% STOK
FY2025 $60M $180M -338.7% -11.2% STOK

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: NUVB (4) vs STOK (4)
Institutional Metric NUVB STOK Criterion Row Winner
Market Capitalization Scale $1.3B $1.8B Larger Scale STOK
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth +242.6% +5.9% Higher Growth NUVB
Operating Margin (TTM) Profitability -61.2% -913.2% Higher Margin NUVB
Net Profit Margin Profitability -67.4% 0.0% Higher Margin STOK
Return on Equity (ROE) Capital Efficiency -49.1% -73.6% Higher ROE NUVB
52-Week Range Position Momentum 2% ($4โ€“$10) 26% ($22โ€“$40) Stronger Trend STOK
Beta / 30D Volatility Risk Regime 1.52ฮฒ ยท 55% Vol 0.83ฮฒ ยท 38% Vol Lower Realized Risk STOK
Unified Institutional Score Composite Signal 61.0 / 100 (BUY) 55.9 / 100 (HOLD) Higher Composite NUVB

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full NUVB vs STOK Buy Guide
NUVB BREAKDOWN
105d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 26th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live NUVB Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
STOK SURGE
7d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 8th %ile
IV Regime Compressed (<25th %ile)
Live STOK Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither NUVB nor STOK registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.